Germline genetic testing and clinical consequences for patients and relatives in onco-urology
Live from the studio: Thematic Session 08
Saturday 10 July
13:15 - 14:15

Location: Virtual Room 2
Chairs: P. Albers, Düsseldorf (DE)
        R.A. Eeles, London (GB)
        B. Faltas, New York (US)
        F.C. Hamdy, Oxford (GB)
        A. Stenzl, Tübingen (DE)

Learning objectives
Genetic testing is an emerging tool for risk consultations. However, the test reliability and the predicted risks differ tremendously. This session will highlight the newest developments on when and how to integrate genetic tests in clinical routine.

13:15 - 13:35 What urologists need to know about germline mutations and prostate cancer management
        R.A. Eeles, London (GB)
        N. Fossati, Milan (IT)
13:25 - 13:35 Discussion
Moderator: F.C. Hamdy, Oxford (GB)
Discussants: R.A. Eeles, London (GB)
             N. Fossati, Milan (IT)

13:35 - 13:55 What urologists need to know about germline mutations and kidney cancer management
        U. Capitanio, Milan (IT)
13:40 - 13:45 Clinical case presentation Germline mutations and kidney cancer management
        M.C. Mir Maresma, Valencia (ES)
13:45 - 13:55 Discussion
Moderator: U. Capitanio, Milan (IT)
Discussants: M.C. Mir Maresma, Valencia (ES)
             W.M. Linehan, Bethesda (US)

13:55 - 14:15 What urologists need to know about germline mutations and urothelial cancer management
13:55 - 14:00 State-of-the-art lecture Germline mutations and urothelial cancer management
        B. Faltas, New York (US)
14:00 - 14:05 Clinical case presentation Germline mutations and urothelial cancer management
        G. Niegisch, Düsseldorf (DE)
14:05 - 14:15 Discussion
Moderator: P. Black, Vancouver (CA)
Discussants: B. Faltas, New York (US)
             G. Niegisch, Düsseldorf (DE)